Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Myelodysplastic Syndrome: early-phase trial registry
46 of 135 indexed Myelodysplastic Syndrome trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #85 of 28,707 conditions by registered trial count.
135 US clinical trials · 46 currently recruiting · #85 of 28,707 conditions by registered trial count
Myelodysplastic Syndrome: 135 US clinical trials tracked, 46 recruiting.
Myelodysplastic Syndrome is the subject of 135 registered US clinical trials on ClinicalTrials.gov, 46 of them currently open to new participants. 7 are in Phase 3-4 (later-stage) and 121 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 33 of these trials.
Enrollment posture brief
Registry condition myelodysplastic-syndrome
OPEN 46 | RECR 34% | LATE 7 | EARLY 121 | RANK #85 | SPON 33
Volume-matched condition peers
Nearest open-share peer: Physical Activity (34% recruiting · 132 trials)
Myelodysplastic Syndrome lists 46 open slots (34% of 135 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Myelodysplastic Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Myelodysplastic Syndrome is recruiting below its size-band peers.
46 of 135 indexed trials (34.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Myelodysplastic Syndrome research.
M.D. Anderson Cancer Center accounts for 33 of 135 trials (24.4%). 51 distinct sponsors appear on at least one study for this condition label.
-
Most Myelodysplastic Syndrome trials plan to enrol fewer than 100 people.
Median target enrolment is 51 among the 135 trials that report a genuine target (sentinel values excluded). 99 of those (73.3%) plan for fewer than 100 participants.
-
Myelodysplastic Syndrome research is mostly interventional.
130 interventional and 5 observational studies make up this index (96.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
135 total, page 3 of 3
Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT00469014
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT00968071
A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
Eisai
NCT00619099
A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia
Mirati Therapeutics
NCT00324220
Oral Clofarabine Study in Patients With Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT00299156
Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
NCT01904136
Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)
H. Lee Moffitt Cancer Center and Research Institute
NCT00831766
INCB018424 in Patients With Advanced Hematologic Malignancies
M.D. Anderson Cancer Center
NCT00674479
Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT01812252
A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML)
Weill Medical College of Cornell University
NCT00875693
T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
Baylor College of Medicine
NCT00368355
Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza
American Regent
NCT01290302
Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML
Traws Pharma
NCT00854945
Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
NCT00569010
Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome
Traws Pharma
NCT01048619
Phase II 5-Azacytidine Plus VPA Plus ATRA
M.D. Anderson Cancer Center
NCT00326170
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
National Cancer Institute (NCI)
NCT00013533
SCT Plus Immune Therapy in Average Risk AML/MDS
New York Medical College
NCT02117297
Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01700673
Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS
New York Medical College
NCT02221310
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
Northside Hospital
NCT02581007
NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases
Masonic Cancer Center, University of Minnesota
NCT01370213
Off-the-shelf NK Cells + SCT for Myeloid Malignancies
M.D. Anderson Cancer Center
NCT05115630
Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation
Memorial Sloan Kettering Cancer Center
NCT00620633
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
Robert Lowsky
NCT02424968
Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes
Celgene
NCT00045786
Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
NCT00402558
Leucovorin for the Treatment of 5 q Minus Syndrome
National Institutes of Health Clinical Center (CC)
NCT00004997
Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk
Traws Pharma
NCT00906334
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
NCT02129582
Study of Clinical Efficacy and Safety of Tosedostat in MDS
Weill Medical College of Cornell University
NCT02452346
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
University of Washington
NCT02121418
Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers
ViaCell
NCT00089596
Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
Jennifer Woyach
NCT04439006
Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy
National Heart, Lung, and Blood Institute (NHLBI)
NCT00433745
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 57 |
| Phase 2 | 64 |
| Phase 3 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Myelodysplastic Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Myelodysplastic Syndrome trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Myelodysplastic Syndrome page
135 registered trials, 46 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 46 Myelodysplastic Syndrome trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Myelodysplastic Syndrome trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Myelodysplastic Syndrome condition card totals 135 registered trials; most-linked intervention Biospecimen Collection; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.